Company Analysis
Sign in

Heron Therapeutics, Inc. (HRTX)

Nasdaq: HRTX · Pharmaceutical Preparations · San Diego, CA · filing with the SEC since 1994
Full chart Alerts Compare
Grade4.3
◀ Past 5.2● Present 4.3▶ Future 3.7
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

52 patents granted to the 3 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Heron Therapeutics, Inc.’s names, not what it holds today.

Patents granted
52
52 utility, 1976 to Dec 31, 2025
Granted in 2025
2
Against 3 in 2024 and 2 in 2023
Applications published
70
3 of them in 2025
Names they are printed under
3
its own name, a former name
By yearGrantedApplications published
'10'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals15
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name3 counted
Heron Therapeutics, Inc. its own name
US, as the owner printed on each patent
35 granted
14 published
Heron Therapeutics, Inc. its own name
named as the applicant on its applications, in US
0 granted
43 published
A.P. PHARMA, INC. a former name
US, as the owner printed on each patent
17 granted
13 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Jun 3, 202512,318,376Compositions of a polyorthoester and an aprotic solventPharmaceuticalsHeron Therapeutics, Inc.
May 6, 202512,290,520Methods of use of emulsion formulations of aprepitantPharmaceuticalsHeron Therapeutics, Inc.
Oct 15, 202412,115,255Methods of use of emulsion formulations of an NK-1 receptor antagonistPharmaceuticalsHeron Therapeutics, Inc.
Oct 15, 202412,115,254Methods of use of emulsion formulations of an NK-1 receptor antagonistPharmaceuticalsHeron Therapeutics, Inc.
Jan 23, 202411,878,074Methods of use of emulsion formulations of an NK-1 receptor antagonistPharmaceuticalsHeron Therapeutics, Inc.
Dec 19, 202311,844,837Compositions of a polyorthoester and an organic acid excipientPharmaceuticalsHeron Therapeutics, Inc.
Sep 5, 202311,744,800Methods of use of emulsion formulations of an NK-1 receptor antagonistPharmaceuticalsHeron Therapeutics, Inc.
Aug 16, 202211,413,350Long-acting polymeric delivery systemsPharmaceuticalsHeron Therapeutics, Inc.
Feb 22, 202211,253,504Compositions of a polyorthoester and an aprotic solventPharmaceuticalsHeron Therapeutics, Inc.
Nov 16, 202111,173,118Emulsion formulations of an NK-1 receptor antagonist and uses thereofPharmaceuticalsHeron Therapeutics, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 25, 20252025/0387487COMPOSITIONS OF A POLYORTHOESTER AND AN ORGANIC ACID EXCIPIENTPharmaceuticalsHeron Therapeutics, Inc.
Jul 17, 20252025/0228867METHODS OF USE OF EMULSION FORMULATIONS OF APREPITANTPharmaceuticalsHeron Therapeutics, Inc.
May 22, 20252025/0161458COMPOSITIONS OF A POLYORTHOESTER AND AN ORGANIC ACID EXCIPIENTPharmaceuticalsHeron Therapeutics, Inc.
Sep 19, 20242024/0307266VIAL ACCESS NEEDLE DEVICEMedical technologyHeron Therapeutics, Inc.
Jul 18, 20242024/0238197METHODS OF USE OF EMULSION FORMULATIONS OF AN NK-1 RECEPTOR ANTAGONISTPharmaceuticalsHeron Therapeutics, Inc.
May 9, 20242024/0148650METHODS OF USE OF EMULSION FORMULATIONS OF AN NK-1 RECEPTOR ANTAGONISTPharmaceuticalsHeron Therapeutics, Inc. · patent 12,115,255 granted from it
May 2, 20242024/0139201METHODS OF USE OF EMULSION FORMULATIONS OF APREPITANTPharmaceuticalsHeron Therapeutics, Inc. · patent 12,290,520 granted from it
May 2, 20242024/0139106METHODS OF USE OF EMULSION FORMULATIONS OF AN NK-1 RECEPTOR ANTAGONISTPharmaceuticalsHeron Therapeutics, Inc. · patent 12,115,254 granted from it
Mar 9, 20232023/0072781METHODS OF USE OF EMULSION FORMULATIONS OF AN NK-1 RECEPTOR ANTAGONISTPharmaceuticalsHeron Therapeutics, Inc. · patent 11,744,800 granted from it
Dec 8, 20222022/0387595COMPOSITIONS OF A POLYORTHOESTER AND AN APROTIC SOLVENTPharmaceuticalsHeron Therapeutics, Inc. · patent 12,318,376 granted from it
What it applied for, 2024 to 2025: Pharmaceuticals 7 · Medical technology 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton HRTX · research, not advice